Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 7/20 | 0.49 |
| ▸ | NRAS | P01111 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27369247 | 1.00 | FLT3 (0.49) | FLT3NRAS | |
| SCHEMBL24574007 | 0.93 | FLT3 (0.45) | FLT3NRAS | |
| SCHEMBL27369774 | 0.93 | FLT3 (0.45) | FLT3NRAS | |
| SCHEMBL27369249 | 0.92 | FLT3 (0.51) | FLT3NRAS | |
| SCHEMBL24574347 | 0.92 | FLT3 (0.51) | FLT3NRAS | |
| SCHEMBL27369163 | 0.90 | FLT3 (0.52) | FLT3NRAS | |
| SCHEMBL24573932 | 0.90 | FLT3 (0.52) | FLT3NRAS | |
| SCHEMBL25989345 | 0.87 | FLT3 (0.54) | FLT3NRAS | |
| SCHEMBL26359533 | 0.87 | FLT3 (0.54) | FLT3NRAS | |
| SCHEMBL25989347 | 0.87 | FLT3 (0.54) | FLT3NRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612410-B2 | Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2026-04-28 | — | — | US | disclosed |
| US-20240294530-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER | 2024-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294530-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK1, IRAK2 | FLT3 1/4885NRAS 372/4885 |
| US-12612410-B2 | Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof | FLT3, IRAK3, IRAK2 | FLT3 1/4885NRAS 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.